FibroGen
Kevin Kwei is a seasoned professional in the field of translational medicine and biomarker research, currently serving as Sr. Director of Translational Medicine at FibroGen, Inc. Previously, Kevin held significant roles including VP of Biomarker and Translational Research at Kartos Therapeutics, Inc., and Senior Director of Biomarker Sciences at Biosplice Therapeutics. Additional experience includes serving as a Director of Translational Medicine and Senior Scientist in Clinical Genetics at Pharmacyclics, an AbbVie Company, as well as working as a Biomarker Consultant at Annexon Biosciences. Kevin Kwei earned a PhD in Cancer Biology from the University of Arizona and a B.S. in Molecular Biology from the University of Wisconsin-Madison.
This person is not in any teams
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.